Neurocrine Biosciences | NBIX - Cash And Equivalent


Neurocrine Biosciences reported $713M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Prothena USD 330.84M 40.6M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Repligen USD 566.02M 182.73M Dec/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024